Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Cash from Operations (2016 - 2025)

Perspective Therapeutics' Cash from Operations history spans 16 years, with the latest figure at 16292000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations fell 584.02% year-over-year to 16292000.0; the TTM value through Sep 2025 reached 84433000.0, down 12031.18%, while the annual FY2024 figure was 18294000.0, 50.44% up from the prior year.
  • Cash from Operations for Q3 2025 was 16292000.0 at Perspective Therapeutics, up from 19953000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 13848000.0 in Q1 2024 and bottomed at 26606000.0 in Q4 2024.
  • The 5-year median for Cash from Operations is 6086000.0 (2022), against an average of 6724421.05.
  • The largest annual shift saw Cash from Operations soared 452.76% in 2021 before it tumbled 584.02% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 2681000.0 in 2021, then tumbled by 327.0% to 6086000.0 in 2022, then plummeted by 48.01% to 9008000.0 in 2023, then crashed by 195.36% to 26606000.0 in 2024, then skyrocketed by 38.77% to 16292000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Cash from Operations are 16292000.0 (Q3 2025), 19953000.0 (Q2 2025), and 21582000.0 (Q1 2025).